LANDSVIRKJUN
14.12.2016 12:02:27 CET | Business Wire | Press release
Landsvirkjun, the National Power Company of Iceland, and Advania have signed a power purchase agreement for the supply of energy to Advania’s Fitjar data centre in the southwest of Iceland. The energy will be supplied by the end of 2016 according to the agreement, which will enable Advania to continue to expand their data center operations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161214005221/en/
Landsvirkjun will supply the energy through its current power station network. The company has supported the growth of the data center industry in recent years in Iceland by offering energy from 100% renewable resources.
Hörður Arnarson, CEO of Landsvirkjun:
"Advania is a welcome addition to Landsvirkjun’s client base. The conditions in Iceland are ideal for data center operations and Landsvirkjun has in recent years actively promoted Iceland as a preferred location for data centers. The successful growth of Advania and other data centers in Iceland is based on favourable, long-term, secure energy contracts, a competitive environment and the cooperation of stakeholders within the industry in Iceland."
Gestur G. Gestsson, CEO of Advania:
"The scope of Advania’s operations, within the data center market, has grown tremendously in recent years and large-scale projects are in the pipeline in the coming months. Access to energy is a key factor in the operation of data centers and we are therefore greatly pleased by this agreement with Landsvirkjun. We believe That Landsvirkjun will strengthen our ability to service more global clients in the future. "
Advania is a leading Nordic IT company with operations in Iceland, Sweden and Norway. The company has around 1000 employees, working from 20 different stations of operation. Advania operates the Steinhella Data Center in Hafnarfjordur and the Fitjar Data Center in Reykjanesbær. The agreement will allow the company to further grow its data center operations and add to its client base.
Landsvirkjun generates 100% of its power from renewable resources. The company owns and operates 16 power stations, including 14 hydropower stations and two geothermal stations as well as two wind turbines. Landsvirkjun is currently constructing a geothermal power station at Þeistareykir in the northeast of Iceland and is also expanding its hydropower station network in Búrfell, in the south of Iceland.
The offering of favourable long-term power purchase agreements makes Iceland a competitive location to set up data centers and the stable, cold climate of the country is particularly suitable for data center operations. Redundant submarine fibre cable system provides the reliable connectivity required by demanding international data centers.
Landsvirkjun has actively promoted Iceland to the responsible parties for determining future locations of data centers. The Company's website contains information on the benefits of Iceland in this regard:
http://www.landsvirkjun.com/datacenters
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005221/en/
Contact:
Landsvirkjun
Magnús Þór Gylfason, +354 515 9000
Director of
Corporate Communications
Magnus.Thor.Gylfason@landsvirkjun.is
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom